Source BioScience to boost stability testing services through $10m acq

By Dan Stanton contact

- Last updated on GMT

Related tags: Mergers and acquisitions

Source BioScience to boost stability testing services through $10m acq
DNA sequencing firm Source BioScience will bolster its stability testing and storage services through a proposed acquisition of Select Pharma Laboratories.

The £6.7m ($10.4m) deal would see Nottingham, UK-based Source BioScience add the pharmaceutical testing and microbiological analysis firm Select, adding additional stability storage and stability testing laboratory services to its client offerings.

These services are “highly complementary,”​ said Source BioScience CEO Nick Ash, who added the acquisition would help the firm meet “increasing demand for stability and pharmaceutical batch release testing services, from a broad spectrum of customers and from territories that Source BioScience does not currently address.”

The merger – expected to be completed in September - would see the firm operate a network of stability storage and laboratory facilities extending from the UK to the East and West coasts of the US, as well as extend the company’s presence in emerging markets including India and China where Select has a commercial presence.

“This proposed acquisition fits squarely with our stated objective of continued expansion through targeted acquisitions, to enhance the breadth and depth of our portfolio of services, in conjunction with ongoing organic growth and development of the existing business,”​ Ash added.

The deal was welcomed by N+1 Singer Equity Research analyst Chris Glasper, who said: “Select’s offering is highly complementary to Source’s stability storage services and will be immediately accretive to earnings… without factoring in any potential cost or revenue synergies.”

Related news

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more